![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Mark Quick
Mark Quick, is responsible for leading Recipharm’s merger and acquisition (M&A) activities. He has been with the company for over 12 years and been an integral part of the international growth and expansion story. During his tenure he has been responsible for most of the 15 or so acquisitions which have been made including those in India, Europe and the US. He also has overall responsibility for Recipharm’s external and internal communications activities including management of the brand. Prior to this, he held various senior leadership roles in supply chain, purchasing and business development with ICI, Medeva, Celltech and UCB. With almost 25 years of experience in the pharmaceutical contract development industry Mark also holds an MBA.
Company:Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.
